Clinical Trials
Below are current clinical trials.
203 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz.
The primary purpose of the HCV-TARGET study is to establish a nationwide registry of patients undergoing treatment with antiviral therapies for chronic hepatitis C (HCV) at both academic and community practices.
-
Scottsdale/Phoenix, Ariz.
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) with and without ribavirin (RBV) for 12 weeks and SOF/GS-5816 FDC for 24 weeks in adults with hepatitis C virus (HCV) infection and Child-Pugh (CPT) class B cirrhosis.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to identify, recruit, and enroll patients with community-acquired pneumonia (CAP) to collect their blood, sputum, urine, and a nasopharyngeal swab for specimen storage. The study also aims to develop a biomarker assay to detect circulating antigen in patients infected with Coccidioides.
-
Rochester, Minn.
This study is to see if PCR test developed at Mayo Clinic to diagnosis C. Difficile infections is able to predict the risk of recurrent infection.
-
Rochester, Minn.
The primary purpose of this study is to evaluate the ability of patients, who are not healthcare workers (HCWs) and have no prior training in swab collection, to collect, package, and ship their own self-collected MT swab specimens (both commercial and Mayo Clinic 3-D printed versions) by following written instructions.
-
Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to prospectively collect longitudinal stool specimens and corresponding clinical and patient provided data from asymptomatic patients or those with history of exposure or patients presenting with symptoms suggestive of COVID-19 who are undergoing testing for the novel SARS-CoV-2 virus to enable high quality research.
-
Rochester, Minn., Jacksonville, Fla.
The first aim of this study is to verify that the TCR beta sequencing and curation platforms we will be using are able to identify patients with severe COVID-19 based on the TCR repertoires. This may be accomplished by testing and analyzing results between two cohorts: patients presenting acutely to MCF with mild COVID-19 and patients presenting with severe COVID-19. This will be accomplished by utilizing the the immunoSEQ Human T-cell Receptor Beta (hsTCB) Assay (Adaptive Biothechnologies) and the publicly available ImmuneCODE Open Access Database to confirm previously published data (PMID: 34253751). Both procedures will be performed by the company that created both platforms, Adaptive Biothechnologies.
The second aim of this study is to sequence the TCR receptors of participating patients and identify TCR motifs that may indicate a predisposition to (or protection from) severe SARS-CoV-2, leading to possible risk stratification of such patients, and whether or not age, gender or ethnicity has any contribution to said risk. This may require that we examine all three cohorts listed in the Subject Information section.
The third aim is to measure SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies to distinguish patients that have not been exposed to SARS-CoV-2 to those that have been exposed.
-
Jacksonville, Fla.
The purpose of this study is to assess levels of caffeine intake among patients who tested positive for COVID-19 infection and compare that to disease severity.
-
Rochester, Minn.
The purpose of this study is to better understand why patients get infectious complications after colon or rectal surgery by identifying the bacteria present on the skin and within the gastrointestinal tract in both healthy volunteers undergoing a colonoscopy, and in patients undergoing colon and rectal surgery. By comparing the bacteria within these two groups, we will better understand the causes of postoperative infectious complications.
-
Rochester, Minn.
The purpose of this study is to develop an advanced multiparametric liver magnetic resonance elastography (MRE) imaging technology for monitoring hepatic inflammation during direct acting antiviral (DAA) treatment, evaluation risks of severe liver injury, and HCC development.